Injectable fillers continue to be an affordable and safe anti-aging treatment for many people looking for a quick-fix for treating wrinkles, enhancing the lips or balancing out the nose.While dermal fillers such as Botox, Restylane and Juvederm are among the most sought-after injectables in today’s non-surgical market, researchers are testing many other compounds so that patients have even more options in the near future.
Aquamid wrinkle fillers have been undergoing trials and testing for several years, and are finally appearing in select cosmetic surgery centers and medical spas around the world.Dr. Rhonda Narins, a dermatologist in New York recently reported on the results of her participation in a study of Aquamid.The 30 patients in her trial project did not experience any problems with the injectable, and did enjoy immediate results. (Source: RealSelf.com)
Aquamid is a transparent injectable that can be used for lip augmentation, smoothing out nasolabial folds, getting rid of deep wrinkles, and even as part of a rhinoplasty procedure.The injectable is physically and chemically stable, and very soft and malleable. Individuals who are allergic to some of other compounds present in today’s leading dermal fillers may be good candidates for this injectable that promises easy administration and no allergic reactions.
In addition to filling out lines and wrinkles, Aquamid can be used to contour the face; surgeons have used it to sculpt high cheekbones, enhance the lips and create more contours around the face for a more sculpted, youthful appearance. Results are immediate, and the filler does not degrade over time; according to the company website, Aquamid provides aesthetic satisfaction for years after the first treatment; It restores facial volume for the long-term, providing natural, lasting results.
According to Contura International, the company that makes Aquamid, the injectable has been used in over 40 countries.It is not yet available in the United States, and may still need to undergo thorough FDA review and trials before reaching the U.S. cosmetic surgery market.